Activated Memory Cytotoxic T-Lymphocytes and T-Cell Receptor Vβ Clonality Predict Treatment-Free Remission After Tyrosine Kinase Inhibitor Discontinuation in Chronic-Phase Chronic Myeloid Leukemia: A 1-Year Prospective Immuno-Monitoring Study
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27062713 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Tatsuro Jo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Japanese Red Cross Nagasaki Genbaku Hospital, Mori-machi 3-15, Nagasaki City 852-8511, Nagasaki, Japan. Hauptthemen laut MEDLINE: T-Lymphocytes, Cytotoxic, Protein Kinase Inhibitors, Receptors, Antigen, T-Cell, alpha-beta, Leukemia, Myeloid, Chronic-Phase. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol Myers Squibb.
Abstract (Originalsprache)
We prospectively evaluated whether cytotoxic T-lymphocyte (CTL) activation and T-cell receptor (TCR) Vβ clonality predict treatment-free remission (TFR) after tyrosine kinase inhibitor (TKI) cessation in chronic-phase chronic myeloid leukemia (CML). Forty-five patients with sustained deep molecular response (DMR) were enrolled (On-TKI, n = 38; Off-TKI, n = 7) and underwent one-year immuno-monitoring from consent. The primary endpoint was 12-month TFR, defined as retention of MR4. Overall, 32/45 patients (71%) maintained TFR at 12 months. Longer TKI exposure and stable DMR were associated with TFR; notably, patients fulfilling “≥7 years of TKI plus ≥1 year of DMR” and exhibiting CTL activation features—CD8 > CD4, memory > effector, and/or highly activated CTL clones on TCR Vβ repertoire—showed the highest likelihood of durable TFR. By contrast, NK cells, effector Tregs, and G-/M-MDSCs did not discriminate TFR status in this cohort. Although antigen specificity against CML stem cells was not directly tested, the memory-dominant CTL phenotype is consistent with immune control after antigen reduction. These findings suggest that a simple, clinically accessible strategy based on flow cytometric CTL profiling and TCR Vβ clonality may help inform TKI discontinuation decisions in CML. External validation is warranted to confirm transportability and refine clinical thresholds.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Japanese Red Cross Nagasaki Genbaku Hospital, Mori-machi 3-15, Nagasaki City 852-8511, Nagasaki, Japan.
- Department of Hematology, Oita Prefectural Hospital, Toyo 2-8-1, Oita City 870-8511, Oita, Japan.
- Department of Infectious Disease, Chugoku Central Hospital, Miyukicho Oazakamiiwanari 148-13, Fukuyama City 720-0001, Hiroshima, Japan.
- Department of Clinical Laboratory, Japanese Red Cross Nagasaki Genbaku Hospital, Mori-machi 3-15, Nagasaki City 852-8511, Nagasaki, Japan.
- Department of Hematology, Chugoku Central Hospital, Miyukicho Oazakamiiwanari 148-13, Fukuyama City 720-0001, Hiroshima, Japan.
- Specimen Analysis Team, Human Resource Development Division, Center for Infectious Disease Education and Research, The University of Osaka, Yamadaoka 2-2, Suita City 565-0871, Osaka, Japan.
ORCID-Profile: Taro Masunari, Ritsuko Kubota-Koketsu
Förderung
- Bristol Myers Squibb
Zitieren
APA
Jo, T., Saburi, Y., Masunari, T., Noguchi, K., Sakai, T., Taguchi, J., Ohtsuka, E., Sezaki, N., Kubota-Koketsu, R., & Kiguchi, T. (2026). Activated Memory Cytotoxic T-Lymphocytes and T-Cell Receptor Vβ Clonality Predict Treatment-Free Remission After Tyrosine Kinase Inhibitor Discontinuation in Chronic-Phase Chronic Myeloid Leukemia: A 1-Year Prospective Immuno-Monitoring Study. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27062713
Vancouver
Jo T, Saburi Y, Masunari T, Noguchi K, Sakai T, Taguchi J, et al. Activated Memory Cytotoxic T-Lymphocytes and T-Cell Receptor Vβ Clonality Predict Treatment-Free Remission After Tyrosine Kinase Inhibitor Discontinuation in Chronic-Phase Chronic Myeloid Leukemia: A 1-Year Prospective Immuno-Monitoring Study. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27062713
BibTeX
@article{Jo2026,
author = {Jo, Tatsuro and Saburi, Yoshio and Masunari, Taro and Noguchi, Kazuhiro and Sakai, Takahiro and Taguchi, Jun and Ohtsuka, Eiichi and Sezaki, Nobuo and Kubota-Koketsu, Ritsuko and Kiguchi, Toru},
title = {Activated Memory Cytotoxic T-Lymphocytes and T-Cell Receptor Vβ Clonality Predict Treatment-Free Remission After Tyrosine Kinase Inhibitor Discontinuation in Chronic-Phase Chronic Myeloid Leukemia: A 1-Year Prospective Immuno-Monitoring Study},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27062713}
}
EUVIMED